Comment on CMS-2026-1255-0001
ICAN, International Cancer Advocacy NetworkSupportAdvocacy
Summary: The International Cancer Advocacy Network (ICAN) supports the proposed action of addressing prior authorization requirements for laboratory testing to prevent delays in patient care. They argue that prior authorization creates unnecessary administrative burdens and barriers to timely biomarker testing, which is essential for precision cancer treatment.
Please see the attached letter from Marcia Horn, President and CEO of ICAN, International Cancer Advocacy Network.